{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:44:52Z","timestamp":1770975892578,"version":"3.50.1"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1097\/inf.0000000000000571","type":"journal-article","created":{"date-parts":[[2014,9,23]],"date-time":"2014-09-23T11:31:11Z","timestamp":1411471871000},"page":"383-391","source":"Crossref","is-referenced-by-count":25,"title":["Review of Tenofovir Use in HIV-infected Children"],"prefix":"10.1097","volume":"34","author":[{"given":"Linda","family":"Aurpibul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanyawee","family":"Puthanakit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20210202","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/526524","article-title":"Pediatric AIDS Clinical Trials Group 219219C Study Team. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.","volume":"46","author":"Patel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R2-11-20210202","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/QAD.0b013e32835a9a2d","article-title":"Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.","volume":"27","author":"Baheti","year":"2013","journal-title":"AIDS"},{"key":"R3-11-20210202","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1128\/AAC.01064-08","article-title":"Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.","volume":"53","author":"Pruvost","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-11-20210202","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1592\/phco.23.6.695.32189","article-title":"Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells.","volume":"23","author":"Robbins","year":"2003","journal-title":"Pharmacotherapy"},{"key":"R5-11-20210202","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1128\/AAC.05317-11","article-title":"Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.","volume":"55","author":"Baheti","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-11-20210202","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R11-11-20210202","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/00126334-200407010-00007","article-title":"Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence.","volume":"36","author":"Stone","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R12-11-20210202","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jadohealth.2011.12.013","article-title":"Predictors of antiretroviral medication adherence among a diverse cohort of adolescents with HIV.","volume":"51","author":"Chandwani","year":"2012","journal-title":"J Adolesc Health"},{"key":"R13-11-20210202","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1128\/AAC.45.10.2733-2739.2001","article-title":"Phase iii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.","volume":"45","author":"Barditch-Crovo","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-11-20210202","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1128\/AAC.48.1.124-129.2004","article-title":"Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.","volume":"48","author":"Hazra","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-11-20210202","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.qai.0000243103.03265.2b","article-title":"Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavirritonavir.","volume":"43","author":"Kearney","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R17-11-20210202","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.","volume":"43","author":"Kearney","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R18-11-20210202","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1128\/AAC.48.6.2091-2096.2004","article-title":"Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.","volume":"48","author":"Taburet","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-11-20210202","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1128\/AAC.00761-07","article-title":"Adolescent Trials Network for HIVAIDS Interventions. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.","volume":"52","author":"Kiser","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-11-20210202","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/QAI.0b013e3182302ea8","article-title":"Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients.","volume":"58","author":"Bouazza","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R22-11-20210202","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1128\/AAC.01334-10","article-title":"P1058 Protocol Team. Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.","volume":"55","author":"King","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-11-20210202","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1345\/aph.1C412","article-title":"Effect of tenofovir on didanosine absorption in patients with HIV.","volume":"37","author":"Pecora Fulco","year":"2003","journal-title":"Ann Pharmacother"},{"key":"R25-11-20210202","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0140-6736(04)16591-4","article-title":"Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.","volume":"364","author":"Martinez","year":"2004","journal-title":"Lancet"},{"key":"R26-11-20210202","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1086\/379829","article-title":"Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine.","volume":"37","author":"Rollot","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R27-11-20210202","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1177\/0091270005281351","article-title":"Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine.","volume":"45","author":"Kearney","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R28-11-20210202","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e328356886d","article-title":"High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.","volume":"26","author":"Sunpath","year":"2012","journal-title":"AIDS"},{"key":"R29-11-20210202","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/381784","article-title":"Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.","volume":"189","author":"Miller","year":"2004","journal-title":"J Infect Dis"},{"key":"R31-11-20210202","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1081\/NCN-100002483","article-title":"Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.","volume":"20","author":"Miller","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"R34-11-20210202","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa0906768","article-title":"AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.","volume":"361","author":"Sax","year":"2009","journal-title":"N Engl J Med"},{"key":"R35-11-20210202","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/infdis\/jir505","article-title":"AIDS Clinical Trials Group Study A5202 Team. Abacavirlamivudine versus tenofovir DFemtricitabine as part of combination regimens for initial treatment of HIV: final results.","volume":"204","author":"Sax","year":"2011","journal-title":"J Infect Dis"},{"key":"R36-11-20210202","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.qai.0000245886.51262.67","article-title":"Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudinelamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changesa 96-week analysis.","volume":"43","author":"Pozniak","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R37-11-20210202","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R38-11-20210202","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/135965350501000207","article-title":"PENTA-13 Study Group. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).","volume":"10","author":"Bergshoeff","year":"2005","journal-title":"Antivir Ther"},{"key":"R39-11-20210202","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"PREDICT-1 Study Team. HLA-B5701 screening for hypersensitivity to abacavir.","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"R40-11-20210202","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/INF.0b013e3182745dba","article-title":"PREDICT Study Group. Prevalence of human leukocyte antigen-B5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use.","volume":"32","author":"Puthanakit","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R43-11-20210202","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3851\/IMP2443","article-title":"HIV STAR Study Group. A randomized comparison of second-line lopinavirritonavir monotherapy versus tenofovirlamivudinelopinavirritonavir in patients failing NNRTI regimens: the HIV STAR study.","volume":"17","author":"Bunupuradah","year":"2012","journal-title":"Antivir Ther"},{"key":"R44-11-20210202","doi-asserted-by":"crossref","first-page":"e846","DOI":"10.1542\/peds.2005-0975","article-title":"Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.","volume":"116","author":"Hazra","year":"2005","journal-title":"Pediatrics"},{"key":"R45-11-20210202","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/INF.0b013e31824bf239","article-title":"A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents.","volume":"31","author":"Della Negra","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R46-11-20210202","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/aid.2008.0302","article-title":"COL40263 Study Team. Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavirlamivudinezidovudine and tenofovir DF (study COL40263).","volume":"25","author":"Ross","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R48-11-20210202","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/INF.0000000000000289","article-title":"A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in human immunodeficiency virus-1 infected children with virologic suppression.","volume":"34","author":"Saez-Llorens","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R52-11-20210202","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","article-title":"Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.","volume":"51","author":"Cooper","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R53-11-20210202","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/524061","article-title":"California Collaborative Treatment Group 578 Team. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.","volume":"197","author":"Goicoechea","year":"2008","journal-title":"J Infect Dis"},{"key":"R54-11-20210202","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1097\/QAD.0b013e3280b07b33","article-title":"The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.","volume":"21","author":"Nelson","year":"2007","journal-title":"AIDS"},{"key":"R55-11-20210202","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3851\/IMP1832","article-title":"DART Trial Team. Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.","volume":"16","author":"Stohr","year":"2011","journal-title":"Antivir Ther"},{"key":"R56-11-20210202","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/INF.0b013e31818c8d2c","article-title":"Collaborative HIV Paediatric Study. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland.","volume":"28","author":"Riordan","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R57-11-20210202","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1468-1293.2007.00497.x","article-title":"Adverse events experienced by three children taking tenofovir and didanosine in combination.","volume":"8","author":"Hawkins","year":"2007","journal-title":"HIV Med"},{"key":"R58-11-20210202","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/INF.0b013e31819ca49a","article-title":"PACTG iDACS 617 Study Team. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors.","volume":"28","author":"Andiman","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R59-11-20210202","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/INF.0b013e31827f4eff","article-title":"Pediatric HIVAIDS Cohort Study. Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection.","volume":"32","author":"Purswani","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R60-11-20210202","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/00044011-200727080-00006","article-title":"Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study.","volume":"27","author":"Vigano","year":"2007","journal-title":"Clin Drug Investig"},{"key":"R61-11-20210202","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e3283333680","article-title":"Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.","volume":"24","author":"Judd","year":"2010","journal-title":"AIDS"},{"key":"R62-11-20210202","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00126334-200403010-00007","article-title":"Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases.","volume":"35","author":"Peyriere","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R63-11-20210202","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/s00467-006-0109-3","article-title":"Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavirritonavir.","volume":"21","author":"Hussain","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"R64-11-20210202","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/11590400-000000000-00000","article-title":"Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study.","volume":"31","author":"Vigano","year":"2011","journal-title":"Clin Drug Investig"},{"key":"R66-11-20210202","doi-asserted-by":"crossref","first-page":"18575","DOI":"10.7448\/IAS.16.1.18575","article-title":"Bone health in children and adolescents with perinatal HIV infection.","volume":"16","author":"Puthanakit","year":"2013","journal-title":"J Int AIDS Soc"},{"key":"R67-11-20210202","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32835192ae","article-title":"Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.","volume":"26","author":"Bedimo","year":"2012","journal-title":"AIDS"},{"key":"R68-11-20210202","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/er.2006-0029","article-title":"Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease.","volume":"28","author":"Chavassieux","year":"2007","journal-title":"Endocr Rev"},{"key":"R69-11-20210202","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/ajcn\/73.4.821","article-title":"Bone mineral content in girls perinatally infected with HIV.","volume":"73","author":"OBrien","year":"2001","journal-title":"Am J Clin Nutr"},{"key":"R70-11-20210202","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/QAD.0b013e328336095d","article-title":"Pediatric AIDS Clinical Trials Group P1045 team. Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045.","volume":"24","author":"Jacobson","year":"2010","journal-title":"AIDS"},{"key":"R71-11-20210202","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/QAI.0b013e31826ea89b","article-title":"Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy.","volume":"61","author":"Puthanakit","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R72-11-20210202","doi-asserted-by":"crossref","first-page":"e872","DOI":"10.1016\/j.ijid.2012.07.019","article-title":"Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents.","volume":"16","author":"Schtscherbyna","year":"2012","journal-title":"Int J Infect Dis"},{"key":"R73-11-20210202","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1542\/peds.2005-2525","article-title":"Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.","volume":"118","author":"Gafni","year":"2006","journal-title":"Pediatrics"},{"key":"R74-11-20210202","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1310\/hct0803-164","article-title":"Study 903E Team. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients.","volume":"8","author":"Cassetti","year":"2007","journal-title":"HIV Clin Trials"},{"key":"R76-11-20210202","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.qai.0000184860.62189.c8","article-title":"A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children.","volume":"40","author":"Giacomet","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R77-11-20210202","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jpeds.2007.12.020","article-title":"Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.","volume":"152","author":"Purdy","year":"2008","journal-title":"J Pediatr"},{"issue":"suppl 2","key":"R78-11-20210202","first-page":"S57","article-title":"Hepatitis B in the HIV-coinfected patient.","volume":"45","author":"Benhamou","year":"2007","journal-title":"JAIDS"},{"key":"R79-11-20210202","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.aids.0000163936.99401.fe","article-title":"EuroSIDA Group. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.","volume":"19","author":"Konopnicki","year":"2005","journal-title":"AIDS"},{"key":"R80-11-20210202","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/QAD.0b013e32810c8bcf","article-title":"Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY).","volume":"21","author":"Piroth","year":"2007","journal-title":"AIDS"},{"key":"R81-11-20210202","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1089\/apc.2006.20.817","article-title":"Aminotransferase elevation in HIVhepatitis B virus co-infected patients treated with two active hepatitis B virus drugs.","volume":"20","author":"Jain","year":"2006","journal-title":"AIDS Patient Care STDS"},{"key":"R82-11-20210202","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/QAD.0b013e32814e6b08","article-title":"Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B.","volume":"21","author":"Hoffmann","year":"2007","journal-title":"AIDS"},{"key":"R83-11-20210202","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1468-1293.2008.00564.x","article-title":"Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.","volume":"9","author":"Omland","year":"2008","journal-title":"HIV Med"},{"key":"R84-11-20210202","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/infdis\/163.5.1138","article-title":"The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state.","volume":"163","author":"Bodsworth","year":"1991","journal-title":"J Infect Dis"},{"issue":"suppl 1","key":"R85-11-20210202","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jhep.2005.11.015","article-title":"Natural history of chronic hepatitis B in co-infected patients.","volume":"44","author":"Puoti","year":"2006","journal-title":"J Hepatol"},{"key":"R86-11-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2009.00781.x","article-title":"BHIVA Viral Hepatitis Working Group. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010.","volume":"11","author":"Brook","year":"2010","journal-title":"HIV Med"},{"key":"R87-11-20210202","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1365-2893.2012.01601.x","article-title":"Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir emtricitabine-based HAART in HBV-HIV-coinfected patients.","volume":"19","author":"Kosi","year":"2012","journal-title":"J Viral Hepat"},{"key":"R88-11-20210202","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1097\/QAD.0b013e32832b43f2","article-title":"Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIVHBV coinfected individuals.","volume":"23","author":"Matthews","year":"2009","journal-title":"AIDS"},{"key":"R89-11-20210202","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/jac\/dkt532","article-title":"Phase III study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.","volume":"69","author":"Markowitz","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R90-11-20210202","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1128\/AAC.00068-10","article-title":"Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleosidenucleotide-resistant HIV.","volume":"54","author":"Lanier","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R91-11-20210202","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/QAD.0b013e328340fdca","article-title":"Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens.","volume":"25","author":"Soler-Palacin","year":"2011","journal-title":"AIDS"},{"key":"R92-11-20210202","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2334-12-18","article-title":"Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.","volume":"12","author":"Pontrelli","year":"2012","journal-title":"BMC Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000000571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T16:38:46Z","timestamp":1650213526000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201504000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000571","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}